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promoters on the DNA-interacting abilities of
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Amparo Caubet,*a Olivier Roubeau,b Luís Korrodi-Gregório,c,d
Ricardo Pérez-Tomásc and Patrick Gamez*a,e
Three copper(II) coordination compounds have been prepared from three diﬀerent 2,2’:6’,2’’-terpyridine-
based ligands, which have been selected to investigate the potential role of supramolecular interactions
on the DNA-interacting and cytotoxicity properties of the corresponding metal complexes. Hence, the
ligands 4’-((naphthalen-2-yl)methoxy)-2,2’:6’,2’’-terpyridine (Naphtpy) and 4’-((1H-benzo[d]imidazol-
2-yl)methoxy)-2,2’:6’,2’’-terpyridine (Bimztpy) have been synthesized from commercially-available
4’-chloro-2,2’:6’,2’’-terpyridine (Cltpy), and their copper(II) complexes have been obtained by reaction with
copper(II) nitrate. The DNA-interacting abilities of the corresponding compounds [Cu(Cltpy)(H2O)(NO3)2]
(1), [Cu(naphtpy)(NO3)(H2O)](NO3)(MeOH) (2) and [Cu(bimztpy)(NO3)(H2O)](NO3) (3) have been investi-
gated using diﬀerent techniques, and cytotoxicity assays with several cancer cell lines have revealed inter-
esting features, viz. the more eﬃcient complex is 2, which although it does not act as a DNA cleaver,
displays the most eﬀective DNA-interacting and cytotoxic properties, compared to 1 and 3.
Introduction
The study of the interaction of metal complexes with nucleic
acids has become an increasingly active field of investigation
after the discovery of the anticancer properties of cisplatin,1–3
one of the most used chemotherapy drugs worldwide.4–6 It is
well known that cisplatin interferes with DNA through binding
to guanine bases,7–10 inducing kinks in the biomolecule,11,12
which leads to cell death (apoptosis).13,14
This platinum drug has several drawbacks, i.e. it is only
eﬃcient for a limited number of cancers,15,16 some tumours may
exhibit acquired or intrinsic resistance to it,17,18 and it pro-
duces severe side eﬀects, such as nausea, nephrotoxicity, oto-
toxicity or myelosuppression.19,20 Therefore, the search for
improved drugs is a perpetual scientific challenge; for
instance, three new platinum-containing compounds have
been developed and marketed, viz. carboplatin, oxaliplatin and
nedaplatin.21,22
Alternative approaches have been developed as well to cir-
cumvent these drawbacks, exploiting other metal ions.23,24
One possible strategy consists of using the redox properties of
a metallic centre to generate reactive oxygen species (ROS) that
will be able to cleave DNA, for example via oxidation of the
deoxyribose unit.25,26 Actually, this approach is based on the
DNA-cleaving properties of bleomycins, a family of natural pro-
ducts with antitumour activity, which originates from their
aptitude to bind transition metals like iron and copper, and to
subsequently produce ROS in the presence of a one-electron
reductant.27–29 Hence, various synthetic coordination com-
pounds mimicking the nuclease activity of bleomycins have
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been reported,30,31 the most studied being (methidiumpropyl-
EDTA)iron(II)32,33 and bis-phenanthroline copper(I).34,35
2,2′:6′,2″-Terpyridine (tpy) is a tridentate ligand that has
widely been used to generate transition-metal complexes.36
Actually, tpy-based metal complexes have found numerous
remarkable applications in various areas of chemistry.37–41
In the field of anticancer drug design, the utilization of tpy-
containing systems is receiving a great deal of attention,42–44
for instance due to their recently recognized propensity to
stabilize G-quadruplex structures.45–47
In the present study, three diﬀerent 4′-substituted tpy
ligands have been used to generate copper(II) complexes, and
their DNA-interacting properties have been investigated and
compared. The ligands naphtpy and bimztpy (Fig. 1) have
been prepared from commercially available Cltpy, and have
been designed to favour π–π interactions (the naphthyl group
in naphtpy) and hydrogen-bonding contacts (the benzimid-
azole ring in bimztpy). Hence, Cltpy does not possess an
additional group favouring supramolecular π–π interactions
while both naphtpy and bimztpy have an aryl substituent that
may promote π-stacking, and bimztpy can also act as a hydro-
gen donor and/or a hydrogen acceptor moiety.
Results and discussion
Ligand synthesis
The ligands naphtpy and bimztpy were prepared by reaction of
respectively 2-naphthalenemethanol or benzimidazol-2-metha-
nol with Cltpy in DMSO in the presence of potassium hydrox-
ide, applying a synthetic procedure described in the literature
(see the Experimental section).48 The single-crystal X-ray struc-
ture of naphtpy could be obtained; the corresponding crystallo-
graphic data are given in Table S1 and a representation of its
molecular structure is depicted in Fig. S1 (see the ESI†).
Complex synthesis and structure
The reaction of one equivalent of copper(II) nitrate trihydrate
with one equivalent of the ligand in methanol at 50 °C leads to
the formation of the corresponding coordination compound.
All complexes are isolated as microcrystalline powders by fil-
tration and are fully characterized (see the Experimental
section).
Single crystals of [Cu(Cltpy)(H2O)(NO3)2] (1) can be
obtained by crystallization in methanol. A representation of
the molecular structure of 1, determined by X-ray diﬀraction,
is shown in Fig. S2 (ESI†). The crystal structure of 1 has been
reported previously;49 the complex is octahedral, with the tpy
ligand and the water molecule occupying the equatorial plane
and the nitrate ions located at the axial positions.49 In the
crystal lattice, the molecules are associated through π–π inter-
actions, generating a supramolecular chain along the crystallo-
graphic axis (Fig. S3a, ESI†). Close contacts between pyridine
rings are observed, as evidenced by the short C2⋯C7 g dis-
tance of 3.375(3) Å, which is slightly below the sum of the van
der Waals radii of two carbon atoms, namely 3.40 Å. In
addition, strong hydrogen bonds (donor⋯acceptor distance of
2.765(2) Å) occur between neighbouring complexes through
the water molecule and nitrate ions, producing a supramolecu-
lar chain along the crystallographic c axis (Fig. S3b, ESI†).
The reaction of one equivalent of naphtpy with one
equivalent of copper(II) nitrate trihydrate yields compound
[Cu(naphtpy)(NO3)(H2O)](NO3)(MeOH) (2). A representation of
the molecular structure of 2, determined by single-crystal X-ray
diﬀraction, is depicted in Fig. 2. Crystallographic and refine-
ment parameters are summarized in Table S2 (ESI†), and
selected coordination bond lengths and angles are listed in
Table S3 (ESI†). First, it should be mentioned that the crystal
lattice of this compound contains two slightly diﬀerent copper
centers, with only some minor divergences regarding coordi-
nation bond lengths and angles. Therefore, only one coordi-
nation geometry is described in detail. The geometry about the
metal ion is a distorted square pyramid, characterized by τ5
values of 0.03 and 0.12 (for the two copper ions).50 The basal
plane is formed by the three nitrogen atoms from the naphtpy
ligand and a water molecule, the apical position being occu-
Fig. 1 Representations of the tpy-based ligands 4’-chloro-2,2’:6’,2’’-
terpyridine (Cltpy), 4’-((naphthalen-2-yl)methoxy)-2,2’:6’,2’’-terpyridine
(Naphtpy) and 4’-((1H-benzo[d]imidazol-2-yl)methoxy)-2,2’:6’,2’’-ter-
pyridine (Bimztpy), together with the labels used for the assignment of
the NMR peaks (in blue for Naphtpy and in red for Bimztpy; see the
Experimental section).
Fig. 2 Representation of the molecular structure of the complex cation
2 with the partial atom-numbering scheme. The hydrogen atoms
(except for those of the coordinated water molecule), the lattice metha-
nol molecule and nitrate ion are omitted for clarity.
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pied by a nitrate anion (Fig. 2). The Cu–N, Cu–Owater and
Cu–Onitrate bond distances are similar to those found for 1, the
nitrate ion being slightly closer in 2 (compared to 1, see
Table S3†). The basal angles, varying from 79.61(9) to 99.80(9)°
(Cu1, Table S3†), reflect the geometrical distortion, which is
mostly due to the small bite angle of the tpy unit.
An examination of the crystal packing of 2 reveals that the
naphthyl group is largely involved in π–π interactions (as
expected, this ligand has been designed to favour the occur-
rence of such supramolecular contacts).
Indeed, molecules of 2 assemble in a head-to-tail fashion
by means of strong stacking interactions as reflected by short
Ctpy⋯Cnaphthyl contact distances, ranging from 3.320(3) to
3.400(4) Å (Fig. 3 and Table S3, ESI†). Furthermore, as occur-
ring in the solid-state structure of 1, the coordinated water
molecule acts as an H-donor group for a nitrate ion of an adja-
cent molecule, forming a dimer (O10⋯O2 and O5⋯O7; Fig. 4
and Table S3, ESI†).
Besides, the coordinated water molecule is also strongly
bonded to a lattice nitrate anion (the corresponding donor⋯-
acceptor contact distances amount to 2.646(3) and 2.630(3) Å;
see Table S3 and Fig. S4, ESI†), giving rise to the formation of
a supramolecular chain (of dimers) along the crystallographic
a axis (Fig. S4, ESI†).
The reaction of one equivalent of bimztpy with one equi-
valent of copper(II) nitrate trihydrate generates copper complex
3, whose molecular structure could not be determined by X-ray
diﬀraction analysis. Indeed, up to now, all attempts to get single
crystals of the compound failed, unfortunately. However,
elemental analysis and mass-spectrometry data (see the Experi-
mental section) of the microcrystalline product allow its formu-
lation as [Cu(bimztpy)(NO3)(H2O)](NO3) (3). Therefore, it may be
expected that the coordination environment of the metal centre
in 3 is analogous to those of 1 and 2 (Fig. S2, ESI†).
UV-Vis spectroscopy
Molecular absorption spectroscopy in the ultraviolet (UV) and
visible (vis) region is an eﬃcient tool to investigate the binding
of (coordination) compounds to DNA.51,52 Therefore, absorp-
tion spectra have been recorded at a constant complex concen-
tration of 25 μM and with increasing amounts of calf-thymus
DNA (ct-DNA), from 0 to 100 μM. The corresponding spectra
for 1 are shown in Fig. 5. Those for 2 and 3 are depicted in
Fig. S5 (ESI†).
Absorption bands in the region 300–400 nm, which are
attributed to metal-to-ligand charge transfer (MLCT), were
used to monitor the interaction of 1–3 with duplex DNA. Hypo-
chromism is clearly observed while increasing quantities of 1
are added to ct-DNA (Fig. 5 and Table 1), which suggests an
electronic interaction between the binding complex and the
biomolecule.53 No redshifts of the absorption bands are
observed; actually, a shift towards a longer wavelength is
indicative of an intercalation binding mode (through stacking
interactions).54,55 Therefore, 1 does not seem to intercalate
between DNA base pairs; rather it appears that 1 tends to
(mostly) interact electrostatically with the double helix.56,57
The magnitude of the binding strength may be estimated
through the determination of the intrinsic binding constant
Kb, applying eqn (1):
56
½DNA
εa  εf ¼
½DNA
ε0  εf þ
1
Kbðε0  εfÞ ð1Þ
Fig. 3 Views of the crystal packing of 2 illustrating the supramolecular
arrangement of the molecules through π–π interactions between
naphthyl and tpy groups. Cg4⋯Cg14’ = 3.872(1) and Cg6⋯Cg12’ =
3.582(1) Å. Symmetry operation: e = −1/2 + x, 1/2 – y, 1/2 + z.
Fig. 4 View of the crystal packing of 2 showing the H-bonding network
connecting two molecules (O10⋯O2 = 2.701(3) and O5⋯O7 = 2.737(3)
Å), and the interaction of a lattice nitrate ion with two water molecules
(O1S⋯O12 = 2.895(7) and O2S⋯O11 = 2.897(7) Å). Symmetry operations:
d = 1 + x, y, z; i = 1 – x, 1 – y, 1 – z.
Fig. 5 Absorption spectra of 1 in Tris-HCl buﬀer (pH = 7.2) upon
addition of ct-DNA. Complex concentration: 25 μM; [ct-DNA]:
0–100 μM. The concentration of ct-DNA was determined from its
absorption intensity at 260 nm with a molar extinction coeﬃcient of
6600 M−1 cm−1. The MLCT band at λ = 337 nm was used to determine
Kb. The red arrow shows the decrease in the absorption intensity with
the increase in concentration of ct-DNA.
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where [DNA] is the concentration of ct-DNA in base pairs, εa is
the extinction coeﬃcient observed at the given ct-DNA concen-
tration, εf is the extinction coeﬃcient of the free complex in
solution (Aobs/[complex]), and ε0 is the extinction coeﬃcient
for the compound in the fully bound form.
The binding constant Kb for 1 amounts to 1.90 × 10
5 M−1
(Table 1), hence suggesting a strong aﬃnity of the compound
for ct-DNA.
Similar features are observed for compound 2 (Fig. S5a,
ESI†), since comparable hypochromism without wavelength
shifting occurs (the % hypochromism value is 13 for 2 while it
is 16 for 1; see Table 1). However, the DNA-binding abilities of
2 are noticeably greater than those of 1 (Kb (1) = 1.90 × 10
5 M−1
and Kb (2) = 3.60 × 10
5 M−1). This diﬀerence most likely arises
from the additional functional group at the 4′-position of the
terpyridine unit (ligand naphtpy; see Fig. 1), namely the
naphthyl moiety. In fact, compared to the UV-vis spectra of 1
(Fig. 5), those of 2 exhibit a strong absorption band at λ =
222 nm (which is absent for 1), which can be ascribed to π–π*
transitions of the naphthyl group (Fig. S5a, ESI†). This absorp-
tion band is strongly aﬀected by the binding to ct-DNA, as
reflected by the corresponding hypochromism of 32%
(Table 1). So, the naphthyl ring apparently is strongly involved
in the binding of the copper complex to DNA, probably
through π-stacking interactions (actually, the ligand naphtpy
has been designed to favour such supramolecular contacts).
Compound 3 shows DNA-binding abilities which are com-
parable to those of 1, viz. Kb (3) = 2.08 × 10
5 M−1 and Kb (1) =
1.90 × 105 M−1 (Table 1). However, the hypochromism induced
by 3 is significantly lower than that caused by 1 (i.e. 6 vs. 16%,
see Table 1), thus indicating that the binding mode of the two
compounds is diﬀerent. Furthermore, the band of 3 at λ =
204 nm (Fig. S5b, ESI†), attributable to π–π* transitions of the
benzimidazole group (as these bands are not observed for the
parent ligand Cltpy; see Fig. 5), are not strongly altered, in con-
trast to the corresponding ones for compound 2 (hypochro-
mism of 12 vs. 32%, see Table 1). These data thus suggest that
the DNA-binding of 3 is diﬀerent from those of 1 and 2. Since
3 possesses hydrogen-donor and hydrogen-acceptor groups
(while 1 and 2 do not), it may be reasonably considered that
hydrogen bonds play an important role in the binding of 3 to
ct-DNA (as anticipated through ligand design).
Fluorescence spectroscopy
Competitive binding studies using ethidium bromide (EB)
bound to ct-DNA and using complexes as fluorescence quench-
ers may provide further comparative information regarding
their DNA-binding aﬃnities. It is well known that EB is a DNA-
intercalating compound that fluoresces when it is bound to
the duplex biomolecule.58,59 Thus, displacement of EB by a
compound that binds to DNA will result in fluorescence
quenching.60
Fluorescence spectra have been recorded at constant con-
centrations of EB and ct-DNA, namely 25 μM, by adding
increasing amounts of the studied complex, viz. in the concen-
tration range 5–200 μM. For the three copper(II) complexes, a
decrease in the emission intensity is observed. The quenching
spectra for compound 1 are shown in Fig. 6, which are repre-
sentative of the other compounds investigated in the present
study (they are complexes 2 and 3; see Fig. S6, ESI†). The
release of EB in all cases confirms that these coordination
compounds indeed interact with ct-DNA, as also indicated by
the UV-vis measurements (see above).
To compare the aﬃnity of complexes 1–3 towards ct-DNA,
their quenching eﬃciency has been assessed by determining
the corresponding Stern–Volmer constant KSV, applying eqn (2)
I0
I
¼ 1þ KSV complex½ : ð2Þ
where I0 is the initial fluorescence intensity of EB (bound to ct-
DNA) and I is the fluorescence intensity in the presence of the
complex (leading to EB displacement). A plot of I0/I versus
[complex] gives a straight line whose slope is equal to KSV. The
KSV constants thus obtained for complexes 1–3 are listed in
Table 2. The trend of the KSV values follows that observed for
the intrinsic binding constants Kb (see above). Indeed, the
highest value, i.e. 4.97 × 103 M−1, is found for compound 2
(Table 2), which also shows the greatest Kb (compared to 1 and
3; see Table 1). Thus, 2 that has a naphthyl group (ligand
Table 1 Intrinsic binding constants Kb and % hypochromism for com-
plexes 1–3 interacting with ct-DNAa
Complex Kb
b (105 M−1) Log Kb % Hypochromism
1 1.90 ± 0.16 5.28 16c
2 3.60 ± 0.11 5.56 13 (32)d
3 2.08 ± 0.09 5.32 6 (12)e
a Linear [DNA]/(εa − εf) vs. [DNA] plots are obtained for
[complex] : [DNA] ratio ≤ 1 : 1. b Kb is obtained from the ratio of the
slope to the intercept (λ = 337 nm (1), λ = 330 nm (2) and λ = 328 nm
(3)). The Kb errors have been determined from the measurement in
triplicate for each complex. c At λ = 337 nm. d At λ = 330 nm (at λ =
222 nm). e At λ = 328 nm (at λ = 204 nm).
Fig. 6 Emission spectra of the DNA-EB complex (25 μM), λexc = 514 nm,
λem = 610 nm, upon addition of increasing amounts of 1 (5–200 μM).
The red arrow shows the diminution of the emission intensity with the
increase in concentration of 1.
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naphtpy) shows the best EB-displacing abilities. Taking into
account that EB is a DNA-intercalating molecule, it may be
assumed that this higher eﬃciency arises from the naphthyl
unit, which may replace EB between base pairs (actually, UV-
vis measurements show that the π–π* transitions corres-
ponding to this group display the highest percentage of hypo-
chromism upon DNA binding; see above and Fig. S5a, ESI†).
The KSV values for 1 and 3 are lower, and the tendency
observed is analogous to that noticed for the binding con-
stants Kb (see above; Table 1). Actually, 3 appears to bind to ct-
DNA with a slightly better eﬃciency than 1 (2.45 vs. 1.45 × 103
M−1, Table 2). It can be mentioned here that displacement of
EB by a molecule does not imply that the latter acts as an inter-
calator (like EB). Indeed, electrostatic interactions or groove
binding may be suﬃcient to alter significantly the confor-
mation of the DNA double helix, which may result in the
release of EB.61,62 Therefore, the benzimidazole unit of the
ligand bimztpy may interact with DNA by means of electro-
static interactions, namely hydrogen bonds involving its N–H
group (which is not the case for Cltpy), provoking a change of
the DNA structure with concomitant loss of EB molecules.
Gel electrophoresis
Agarose gel electrophoresis has been subsequently employed
to observe directly the interaction of compounds 1–3 with
plasmid DNA. Hence, the potential DNA-cleaving abilities of
1–3 were evaluated by electrophoretic mobility measurements
with pBR322 plasmid DNA. A reducing agent, namely ascorbic
acid, has been used as well to simulate the reducing environ-
ment found in most cellular compartments (the physiological
concentrations of ascorbic acid range from 100 to 400 μM).
The generation of copper(I) species will permit the potential
formation of reactive oxygen species (ROS) that are capable of
cleaving DNA. The corresponding agarose gels are depicted in
Fig. 7. First, it should be noted that complexes 1 and 3 exhibit
similar behaviour while that of 2 is clearly distinct. For 1
(Fig. 7a, left), without a reducing agent, the complex concen-
trations of 5–20 µM do not aﬀect the DNA since the bands
observed (lanes 2–4), corresponding to forms I and II (super-
coiled and circular nicked forms, respectively), and their inten-
sity are similar to those of the native biomolecule (lane 1).
From a complex concentration of 40 µM (lane 5), a clear
increase in the intensity of the band for form II is noted,
which is associated with a vanishing of the band corres-
ponding to form I; in addition, a new band appears between
those of forms I and II, which is ascribed to form III (linear
form, lane 5) that is produced when both DNA strands are
broken. It thus appears that 1 acts as an eﬃcient DNA cleaver
when concentrations superior to 40 µM are used, as evidenced
in lanes 5–8 (Fig. 7a, left), where an increase in the band inten-
sity for both forms II and III is noticed together with the com-
plete disappearance of the band corresponding to form I. In
the presence of a reducing agent (Fig. 7b, right), comparable
features are observed but the DNA cleavage is achieved at
lower complex concentrations (Fig. 7a, right); indeed, the com-
plete loss of form I is obtained for a complex concentration of
20 µM (lane 5, Fig. 7a, right), while 60 µM of 1 are required
without ascorbic acid (lane 6, Fig. 7a, left). Moreover, the
plasmid DNA is completely degraded when using complex con-
centrations above 40 µM (no bands are observed in lanes 6–8),
and this does not occur without the reducing agent (with
complex concentrations up to 100 µM; Fig. 7a, left). Conse-
quently, the DNA-cleaving properties of 1 are improved in the
presence of ascorbic acid, most likely as the result of the pro-
duction of higher amounts of ROS.
For 2, a drastically diﬀerent behaviour is observed (Fig. 7b).
Actually, without a reducing agent, the intensity of the bands
(for both form I and form II) decreases when the concen-
tration of the complex is increased, and the generation of form
III does not take place (Fig. 7b, left). These results are indica-
tive of the occurrence of strong DNA–2 interactions,56 without
strand cleavage. Compound 2 may simply act as an eﬃcient
DNA binder (in fact, the largest Kb and KSV values have been
obtained with 2; see above), giving rise to the formation of
voluminous DNA-complex species such as DNA dimers,
trimers and so on (bound to metal complexes), which
Table 2 Stern–Volmer constants KSV determined for complexes 1–3
competing with ethidium bromidea
Complex KSV (10
3 M−1) Log KSV
1 1.45 ± 0.05 3.16
2 4.97 ± 0.33 3.70
3 2.45 ± 0.20 3.39
a KSV is obtained from the slope of the linear Stern–Volmer plot. The
KSV errors have been determined from the measurement in triplicate
for each complex.
Fig. 7 Agarose gel electrophoresis images of pBR322 plasmid DNA (15
µM b.p.) incubated for 1 h at 37 °C with increasing concentrations of (a)
complex 1, (b) complex 2 and (c) complex 3, without (left) or in the pres-
ence of a reducing agent (right), i.e. ascorbic acid (100 µM), during an
additional incubation time of 1 h (lanes 2–8). Left: lane 1: pure plasmid
DNA; lane 2: [complex] = 5 μM; lane 3: [complex] = 10 μM; lane 4:
[complex] = 20 μM; lane 5: [complex] = 40 μM; lane 6: [complex] =
60 μM; lane 7: [complex] = 80 μM; lane 8: [complex] = 100 μM. Right:
Lane 1: pure plasmid DNA; lane 2: pBR322 plasmid DNA + ascorbic acid
(100 µM); lane 3: [complex] = 5 μM; lane 4: [complex] = 10 μM; lane 5:
[complex] = 20 μM; lane 6: [complex] = 40 μM; lane 7: [complex] =
60 μM; lane 8: [complex] = 80 μM.
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precipitate and result in the vanishing of the bands. When
ascorbic acid is used (Fig. 7b, right), vanishing of the bands
also takes place (lanes 3 and 4), but some cleavage is observed
as well, since the intensity of the band ascribed to form II
increases with the complex concentration (concentrations of 2
above 20 µM; lanes 5–8), and form I is eliminated when a
complex concentration above 60 µM is used (lanes 7 and 8;
Fig. 7b, right). Accordingly, some quantities of ROS are gener-
ated that begin to aﬀect the plasmid DNA.
Complex 3 exhibits a behaviour that is analogous to that of
1. Without a reducing agent (Fig. 7c, left), the compound does
not aﬀect the biomolecule with concentrations up to 20 µM
(lanes 2–4). Above this concentration, the band corresponding
to form II intensifies progressively with the concentration,
while that of form I decreases (lanes 5–8). In the present case,
however, emergence of form III is not observed as for 1. Thus,
without ascorbic acid, 3 appears to be a less eﬃcient DNA
cleaver than 1. In contrast, when a reducing agent is added,
the cleaving properties of 3 are significantly better than those
of 1 (Fig. 7a and 7c, right); indeed, form III is already gener-
ated with 5 µM of 3 (Fig. 7c right, lane 3), whereas 10 µM of 3
are required to detect linear DNA (Fig. 7a right, lane 4). DNA
form I is completely damaged with a complex concentration of
10 µM (lane 4), while it is 20 µM for 1 (lane 5). Above a
complex concentration of 40 µM, the plasmid DNA is comple-
tely degraded (lanes 6–8).
In summary, the electrophoretic results corroborate the
stronger DNA-binding aﬃnity of 2 observed by UV-Vis and
fluorescence spectroscopy (see above). Interestingly, 1 and 3
are very eﬃcient DNA cleavers, contrary to 2. It appears that
the strong binding of 2 to DNA avoids DNA degradation by
ROS; the ROS-generation abilities of 2 seem to be “silenced”
through DNA binding.
We have also performed similar gel-electrophoresis studies
with the free ligands in the absence and presence of a redu-
cing agent, namely ascorbic acid. As is evidenced in Fig. 8
(experiments carried out without a reducing agent), Cltpy,
Naphtpy and Bimztpy do not aﬀect at all the electrophoretic
mobilities of pBR322 plasmid DNA. The same features are
observed in the presence of ascorbic acid (results not shown).
AFM studies
pBR322 plasmid DNA was incubated at 37 °C for 1 hour with
the diﬀerent complexes ([complex] = 5 µM) in 40 mM HEPES–
10 mM MgCl2 buﬀer, as for the corresponding gel electrophor-
esis experiments (see the Experimental section), for compari-
son purposes. The atomic-force microscopy (AFM) images
obtained are presented in Fig. 9. Fig. 9a shows the original
morphology of the pBR322 plasmid DNA used for these
studies, without (left) and with (right) the reducing agent (i.e.
ascorbic acid), characterized by the presence of open circular
structures with some supercoiling. Clearly, the incubation of
the biomolecule with complexes 1–3 aﬀects significantly its
structure (Fig. 9b–d, respectively). For 1, without the reducing
agent, some linear, cleaved DNA is observed together with
open circular structures (Fig. 9b, left). When the reducing
Fig. 8 Agarose gel electrophoresis images of pBR322 plasmid DNA (15
µM b.p.) incubated for 1 h at 37 °C with increasing concentrations of the
free ligand (a) Cltpy, (b) Naphtpy and (c) Bimztpy, without a reducing
agent. Lane 1: pure plasmid DNA; lane 2: [free ligand] = 5 μM; lane 3:
[free ligand] = 10 μM; lane 4: [free ligand] = 20 μM; lane 5: [free ligand]
= 40 μM; lane 6: [free ligand] = 60 μM; lane 7: [free ligand] = 80 μM;
lane 8: [free ligand] = 100 μM. The same results are observed in the
presence of ascorbic acid (reducing agent).
Fig. 9 AFM images of (a) pure pBR322 plasmid DNA (without and with
ascorbic acid); (b–d) pBR322 plasmid DNA in the presence of complexes
1–3, respectively (left: without ascorbic acid; right: with ascorbic acid).
[DNA] = 15 µM b.p.; [complex] = 5 µM.
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agent is added, only linear forms are noticed, corroborating
the DNA-cleaving properties of 1 observed by gel electrophor-
esis (see above). As already revealed by the electrophoretic
results and the spectroscopic studies, complex 2 exhibits a
drastically distinct behaviour. Indeed, with or without the
reducing agent (Fig. 9c), 2 induces the formation of super-
coiled forms with some globular aggregates (Fig. 9c right),
which is indicative of a high aﬃnity of the compound for DNA.
No linearized forms are detected (even with the reducing
agent; Fig. 9c right), which confirms that the interaction of 2
with DNA does not result in its cleavage. Finally, 3 without the
reducing agent displays DNA-interacting properties, which are
reflected by the formation of supercoiled forms (Fig. 9d, left).
This feature suggests that 3 can bind to DNA thanks to its aro-
matic benzimidazole substituent (actually the Kb and KSV
values for 3 are higher than those for 1, which does not induce
supercoiling; see above). In the presence of a reducing agent, 3
cleaves the DNA eﬃciently (only linear forms are detected;
Fig. 9d right), confirming the electrophoretic results (see
above). In summary, as for the gel electrophoresis, the AFM
studies show that 1 and 3 act as DNA cleavers, in contrast to 2.
ROS generation
The production of ROS mediated by complexes 1–3 was first
evaluated using ascorbic acid (AA); in the presence of ascor-
bate and dioxygen, Cu2+ will indeed generate ROS.63 The reac-
tions were followed by measuring the AA consumption
through its absorbance at 265 nm (pH 7.4, see the Experi-
mental section),64 and the corresponding results are depicted
in Fig. 10a. Without any copper catalyst (blank experiment), a
very slight decrease in absorbance is observed (Fig. 10a).
In contrast, in the presence of copper(II) ions (i.e. CuCl2), a
rapid consumption of AA takes place, which is total after
ca. 10 minutes. Compound 1 also generates a great amount
of ROS, but less than CuCl2. Finally, compounds 2 and 3
exhibit similar behaviour, viz. both complexes are capable of
producing ROS, but this production is clearly inferior com-
pared to that mediated by CuCl2 and 1 (Fig. 10a). It can be
noticed that 2 appears to generate slightly more ROS than 3,
which again suggests that the ROS-generation abilities of 2 are
not operative upon binding to DNA (see above). Furthermore,
the results achieved with 1 confirm that it is the most eﬃcient
ROS generator, which results in significant DNA cleavage.
Next, the potential formation of hydroxyl radicals was
investigated with a highly specific fluorescent probe, namely
coumarin-3-carboxylic acid (CCA).65,66 The metal-mediated for-
mation of 7-hydroxy-coumarin-3-carboxylic acid (7-OH-CCA),
through the reaction of CCA with HO• radicals, was followed
by fluorescence spectroscopy at pH 7.4, using the excitation
wavelength of 7-OH-CCA, i.e. 385 nm, which emits at
500 nm (see the Experimental section). The resulting
7-OH-CCA emission versus time curves is shown in Fig. 10b.
Without copper (blank experiment), a slight increase in
7-OH-CCA fluorescence is observed, whereas the production of
7-OH-CCA is drastically enhanced in the presence of CuCl2.
Surprisingly, compound 1, which exhibits significant ROS-
generating properties (see above; Fig. 10a), is not able to catalyse
the formation of great amounts of 7-OH-CCA (Fig. 10b). This
result may be explained by a reaction occurring at the ligand,
the copper complex thus acting as a self-hydroxyl-radical
scavenger.67,68 Compounds 2 and 3 also act as scavengers
(particularly compound 3); however, some production of
7-OH-CCA is observed with 2, which conversely does not cleave
DNA (contrary to 1 and 3).
In summary, these experiments suggest that the strong
DNA-binding aﬃnity of 2 overrides its DNA-cleaving properties
(as already indicated by the electrophoretic and AFM studies).
Cytotoxicity assays
Cell-viability assays were carried out with the free ligands
Cltpy, Naphtpy and Bimztpy and complexes 1–3. In the first
instance, each compound was screened by means of single-
point assays, using two diﬀerent concentrations, namely 10
and 50 µM, in six cancer cell lines, i.e. A549 (lung adeno-
carcinoma), A375 (melanoma), MCF-7 (breast adeno-
carcinoma), PC3 (prostate adenocarcinoma), SKOV3 (ovary
Fig. 10 (a) Consumption of ascorbic acid (AA) mediated by CuCl2 and
complexes 1–3; [CuCl2] = [complex] = 1 μM; [AA] = 100 μM; 100 mM
phosphate buﬀer, pH 7.4. (b) Generation of 7-hydroxy-coumarin-3-car-
boxylic acid (7-OH-CCA; λexc = 385 nm, λem = 500 nm) via metal-
mediated hydroxylation (HO•) of coumarin-3-carboxylic acid (CCA);
[CuCl2] = [complex] = 10 μM; [AA] = 300 μM; [CCA] = 1 mM; 100 mM
phosphate buﬀer, pH 7.4.
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adenocarcinoma) and SW620 (colorectal adenocarcinoma).
The corresponding results obtained after an incubation time
of 24 hours are shown in Fig. S7 and Table S4† for [compound]
= 10 µM, and in Fig. 11 and Table 3 for [compound] = 50 µM.
At a compound concentration of 10 µM, only complex 2 is
capable of aﬀecting cell viability with more than 50% of cell
death in MCF-7 (breast adenocarcinoma), after an incubation
time of 24 hours (see Table S4†). At higher [compound],
namely 50 µM, the cytotoxic behavior of complex 2 is con-
firmed, since it shows good eﬃciencies for almost all cell lines
tested (Fig. 11 and Table 3); for instance, only 5% of the
MCF-7 cells are still viable after an incubation time of
24 hours (Table 3). It is really interesting to note that complex
2 exhibits the best cytotoxicity properties. Indeed, from the gel-
electrophoretic results (see above), one may have expected that
complexes 1 and 3 would show better cytotoxicity properties
than 2, since 1 and 3 act as DNA cleavers, in contrast to 2.
Therefore, it appears that the stronger DNA-binding behavior
presented by 2 (in comparison with that of 1 and 3; see UV-vis
and fluorescence spectroscopic studies) may be linked to its
higher cytotoxic properties.
It can also be noticed that the free ligand Cltpy shows good
cytotoxicity activity towards colon-cancer SW620 cells, with a
cell viability of 17%, after one-day incubation time (Fig. 11 and
Table 3). Similar experiments have also been performed apply-
ing an incubation time of 48 hours (see Fig. S8 and Table S5†).
After two days of incubation and [compound] = 10 µM, good
cytotoxicity (cell-viability values below 40%; Fig. S8A†) is
observed for all compounds in the skin-cancer A375 cell line.
Furthermore, complexes 1–3 show substantial cytotoxicity
against breast-cancer MCF-7 cells, with cell-viability values in
the range 24–29% (Table S5†). At a compound concentration
of 50 µM and incubation time of 48 hours, complex 2 is able
to decrease the viability of almost all the types of cancer cells
tested in the present study (Fig. S8B†); in particular, the skin-,
breast- and colon-cancer cells are completely eradicated
(Table S5†), and low cell-viability values are observed for the
other cancer-cell lines (Table S5†). Complex 1 exhibits good
cytotoxicity for three cell lines, namely lung A549, breast
MCF-7 and ovary SKOV3 (Table S5†). Finally, complex 3 is
active against breast MCF-7 and colon SW620 cells (Table S5†).
Regarding the free ligands, it appears that the colon-cancer
cells SW620 are the most sensitive to them (Table S5†).
Since all three complexes display notable cytotoxicity pro-
perties towards breast MCF-7 cancer cells, half maximal inhibi-
tory concentration (IC50) values for all compounds have been
determined for this cell line. The corresponding results, after
an incubation time of 24 hours, are shown in Fig. 12, and
listed in Table 4. For comparison purposes, IC50 values have
also been obtained for cisplatin, the reference coordination
compound used clinically,2 and the copper/phenanthroline
complex ([Cu(phen)2]X2; X = NO3)
69 which is the reference
molecule for copper-based systems35 (Table 4). As expected,
from all compounds reported herein, complex 2 presents the
best IC50 value, i.e. 12 µM, which is much lower than that of
cisplatin (that is 65 µM; Table 4). The reference copper/
phenanthroline complex, which is a DNA-cleaving agent35 (con-
trary to 2), exhibits the best cytotoxicity properties, as reflected
by its IC50 value of 3.9 µM (Table 4). However, it should be
noticed that complex 2, like complex 3, Naphtpy and Bimztpy,
gives a lower IC25 value than [Cu(phen)2]
2+ (Table 4). Finally,
Fig. 11 Cell-viability assays (single-point screening, % of cell viability) of
the free ligands Cltpy, Naphtpy and Bimztpy and complexes 1–3 with
diﬀerent cancer cell lines, namely A549 (lung adenocarcinoma), A375
(melanoma), MCF-7 (breast adenocarcinoma), PC3 (prostate adeno-
carcinoma), SKOV3 (ovary adenocarcinoma) and SW620 (colorectal
adenocarcinoma), using [compound] = 50 µM and an incubation time of
24 h. The results are means ± SD of three separate experiments.
Table 3 Cell-viability assays (single-point screening, % cell viability) of the free ligands and the copper complexes 1–3 in diﬀerent cancer-cell lines,
i.e. A549 (lung adenocarcinoma), A375 (melanoma), MCF-7 (breast adenocarcinoma), PC3 (prostate adenocarcinoma), SKOV3 (ovary adeno-
carcinoma) and SW620 (colorectal adenocarcinoma), using a pre-set [compound] of 50 μM (single-point assay) and an incubation time of 24 h. The
data shown are means ± SD of three independent experimentsa
Compound
Cell line
A549 A375 MCF-7 PC3 SKOV3 SW620
Cltpy 43 ± 3.0 30 ± 1.9 55 ± 6.3 65 ± 0.6 52 ± 1.5 17 ± 2.4
1 60 ± 8.4 56 ± 7.9 39 ± 2.3 71 ± 3.7 51 ± 6.4 71 ± 6.1
Naphtpy 50 ± 2.5 33 ± 2.7 56 ± 4.5 42 ± 3.5 37 ± 1.6 34 ± 4.7
2 23 ± 4.6 9 ± 1.1 5 ± 0.9 29 ± 1.3 21 ± 1.0 12 ± 1.4
Bimztpy 37 ± 1.8 41 ± 3.6 48 ± 0.7 60 ± 1.5 56 ± 5.0 38 ± 7.5
3 67 ± 5.9 56 ± 4.6 39 ± 4.0 63 ± 9.5 36 ± 1.4 70 ± 8.2
a Cell viabilities ≤25% are shown in bold.
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determination of the IC75 values reveals that besides complex
2, complex 3 shows some activity (although much lower than
the DNA cleaver [Cu(phen)2]
2+).
Conclusions
In the present study, three terpyridine-based ligands, bearing
diﬀerent R groups at position 4′ (R = Cl, naphthyl or benzimi-
dazole), have been used to generate copper(II) complexes, with
the objective to examine the role played by distinct types of
supramolecular interactions on their DNA-interacting and
cytotoxic properties. Interestingly, the results obtained show
that the most eﬃcient metal complex is 2, which contains the
naphthyl group and exhibits the best DNA-interacting pro-
perties. Unexpectedly, complexes 1 and 3, which are capable of
cleaving the DNA strands (whereas 2 cannot), are significantly
less cytotoxic than 2 (at least in the cell lines tested). Therefore,
a coordination compound displaying DNA-cleaving abilities
will not necessarily exhibit greater cytotoxicity behaviour than
a related complex which does not act as a DNA cleaver. The
strong DNA-interacting properties of the naphthyl group
(through supramolecular π–π interactions) of 2 appear to be a
critical issue regarding its biological activity.
Subsequent studies will be dedicated to investigate the
influence of larger aryl substituents (e.g. anthracenyl, pyrenyl)
and of spacers of diﬀerent lengths between the aryl group and
the terpy moiety on the biological properties of new copper(II)
complexes derived from 2.
Experimental section
General methods
All reactions were performed under aerobic conditions and all
reagents and solvents were purchased from Sigma-Aldrich or
Acros Organics. The reference copper(II)–phenanthroline
complex [Cu(H2O)(1,10-phenanthroline)2](NO3)2 was prepared
following the procedure described by K. J. Catalan et al.69
pBR322 plasmid DNA was purchased from Roche and calf
thymus DNA was obtained from Sigma-Aldrich. 1H, 13C {1H}
and heteronuclear {1H–13C}-HSQC NMR spectra were recorded
at room temperature with a Varian Unity 400 MHz spectro-
meter. Proton and carbon chemical shifts are expressed in
parts per million (ppm, δ scale) and are referenced to the peak
of the solvent used. Infrared spectra (as KBr pellets) were
recorded using a Nicolet-5700 FT-IR (in the range
4000–400 cm−1), and data are represented as the frequency of
absorption (cm−1). Elemental analyses were performed by the
Servei de Microanalisi, Serveis Cientificotècnics of the Univer-
sity of Barcelona. UV-Vis experiments were performed with
a Varian Cary-100 spectrophotometer. The fluorescence
measurements were carried out with a KONTRON SFM 25
spectrofluorometer. ESI mass spectroscopy was carried out
using a LC/MSD-TOF Spectrometer from Agilent Technologies,
equipped with an electrospray ionization (ESI) source at the
Serveis Cientificotècnics of the University of Barcelona.
Preparation of the ligands naphtpy and bimztpy
The ligands were synthesized by reaction of 2-naphthalene-
methanol or benzimidazol-2-methanol with 4′-chloro-2,2′:6′,2″-
terpyridine (Cltpy) in DMSO in the presence of potassium
hydroxide, following a known procedure.48
Synthesis of 4′-((naphthalen-2-yl)methoxy)-2,2′:6′,2″-terpyri-
dine (naphtpy). 0.100 g (0.632 mmol) of 2-naphthalenemetha-
nol was added to a suspension of KOH (0.039 g; 0.700 mmol)
in 15 mL of dry DMSO. After stirring for 30 minutes at 70 °C,
0.165 g (0.620 mmol) of Cltpy was added, and the resulting
reaction mixture was further stirred for 4 hours at 70 °C. Sub-
sequently, this reaction mixture was poured into 150 mL of ice
water. The white precipitate formed was filtered oﬀ, washed
with cold water and chloroform (3 × 5 mL), and dried under
reduced pressure. Yield = 0.199 g (0.512 mmol, 81%). Anal.
calcd for [naphtpy + 0.35 DMSO], C26.7H21.1N3SO1.35: C, 77.10;
H, 4.89; N, 9.76. Found: C. 76.94; H, 5.10; N, 10.08. ESI-MS:
m/z = 390.23 [M + H]+, 141.07 [(2-methyl)naphthalene-H]+.
1H NMR (400 MHz, d6-DMSO): δ (ppm) = 8.72 (d, 2H, J =
4.0 Hz, Ha), 8.62 (d, 2H, J = 8.0 Hz, Hd), 8.12 (s, 2H, He), 8.08
Table 4 IC25, IC50 and IC75 values (µM) of the free ligands Cltpy,
Naphtpy and Bimztpy and complexes 1–3 for the MCF-7 cell line (breast
adenocarcinoma), after 24 h incubation ± SD of three independent
experiments
Compound IC25 IC50
a,b IC75
a
Cltpy 11 ± 1.3 N.D. N.D.
1 3.4 ± 0.40 43 ± 9.9 N.D.
Naphtpy 1.2 ± 0.17 N.D. N.D.
2 1.33 ± 0.19 12 ± 0.97 22 ± 3.7
Bimztpy 1.65 ± 0.63 35 ± 1.8 N.D.
3 2.2 ± 0.12 34 ± 3.7 70 ± 1.7
Cisplatin 35 ± 3.8 65 ± 2.8 N.D.
[Cu(phen)2]
2+ 2.6 ± 0.68 3.9 ± 0.35 8.6 ± 3.7
aN.D. = not determined. b The lowest IC50 values are shown in bold.
Fig. 12 IC50 values (µM) from the dose–response assay of the
ligand Bimztpy, the complexes 1–3 and the reference compounds
cisplatin and [Cu(H2O)(1,10-phenanthroline)2](NO3)2
69 (symbolized as
[Cu(phen)2]
2+) in the MCF-7 cell line, after an incubation time of
24 hours (see Table 4). The results shown are means ± SD of triplicate
experiments.
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(s, 1H, Hf), 8.01 (m, 2H, Hc), 7.99 (m, 1H, Hh), 7.96 (m, 1H,
Hg), 7.67 (d, 2H, J = 4.0 Hz, Hi), 7.54 (m, 2H, Hb), 7.49 (m, 2H,
Hj), 5.58 (s, 2H, Hk).
13C NMR (400 MHz, d6-DMSO): δ (ppm) =
166.2 (Ce″), 156.8 (Ce′), 154.8 (Cd′), 149.3 (Ca), 137.4 (Cc),
133.9 (Ck′), 132.8 (Cf′), 132.6 (Ch′), 128.1 (Ch), 127.9 (Cg), 126.4
(Cf), 126.2 (Cb), 125.5 (Ci), 124.6 (Cj), 120.9 (Cd), 107.2 (Ce),
69.6 (Ck). IR (KBr): ν = 3426, 1583, 1561, 1404, 1196, 1022,
796 cm−1.
Synthesis of 4′-((1H-benzo[d]imidazol-2-yl)methoxy)-2,2′:6′,2″-
terpyridine (bimztpy). 0.250 g (1.67 mmol) of benzimidazol-2-
methanol was added to a suspension of KOH (0.470 g;
8.38 mmol) in 12 mL of dry DMSO. After stirring for
30 minutes at 70 °C, 0.452 g (1.68 mmol) of Cltpy was added,
and the resulting reaction mixture was further stirred for
4 hours at 70 °C. Subsequently, this reaction mixture was
poured into 150 mL of ice water. The white precipitate formed
was filtered oﬀ, washed with cold water and dried. Yield =
0.259 g (0.68 mmol, 41%). Anal. calcd for [bimztpy + 2H2O],
C23H21N5O3: C, 66.50; H, 5.09; N, 16.85. Found: C, 65.52;
H, 5.23; N, 16.99. ESI-MS: m/z = 781.28 [2M + Na]+, 402.13
[M + Na]+, 380.15 [M + H]+. 1H NMR (400 MHz, d6-DMSO):
δ (ppm) = 8.73 (d, 2H, J = 4.3 Hz, Ha), 8.62 (d, 2H, J = 7.9 Hz,
Hd), 8.14 (s, 2H, He), 8.01 (dd, 2H, J = 7.7 Hz, Hc), 7.57 (m, 2H,
Hf), 7.51 (dd, 2H, J = 4.3 Hz and J = 7.7 Hz, Hb), 7.20 (dd, 2H,
J = 5.9 Hz and J = 3.1 Hz, Hg), 5.64 (s, 2H, Hk).
13C NMR
(400 MHz, d6-DMSO): δ (ppm) = 166.3 (Ce″), 157.0 (Ce′),
154.9 (Cd′), 149.6 (Ck′), 149.5 (Ca), 137.7 (Cf′), 137.6 (Cc),
124.8 (Cb), 124.8 (Cf), 122.3 (Cg), 121.3 (Cd), 107.4 (Ce),
64.2 (Ck). IR (KBr): ν = 3187, 1583, 1565, 1348, 739 cm
−1.
Preparation of the copper(II) complexes
0.41 mmol of the ligand were suspended in 40 mL of methanol
and heated at 50 °C until complete dissolution. To this solu-
tion, 0.100 g (0.41 mmol) of copper(II) nitrate trihydrate in
10 mL of methanol were added. The resulting mixture was
stirred at 40 °C for 2 hours and then left for the slow evapor-
ation of the solvent. After a few days, a precipitate or crystals
appeared, which was filtered oﬀ, washed with ethyl ether and
dried under reduced pressure.
[Cu(Cltpy)(H2O)(NO3)2] (1). Yield: 98 mg [51%]. Anal. calcd
for C15H12ClCuN5O7 (%): C, 38.07; H, 2.56; N, 14.80. Found:
C, 37.94; H, 2.61, N, 14.77. IR (KBr): ν = 3414, 3098, 1585,
1561, 1445, 1416, 1404, 1274, 1112, 1017, 802 cm−1.
[Cu(H2O)(naphtpy)(NO3)](NO3) (2). Yield: 192 mg [79%].
Anal. calcd for C26H21CuN5O8 (%): C, 52.48; H, 3.56; N, 11.77.
Found: C, 52.46; H, 3.19, N, 11.79. IR (KBr): ν = 3493, 3061,
1617, 1474, 1383, 1222 cm−1.
[Cu(bimztpy)(H2O)(NO3)](NO3) (3). Yield: 204 mg [81%].
Anal. calcd for {[Cu(bimztpy)(H2O)(NO3)](NO3) + 1.5H2O}
C23H23CuN7O9.5 (%): C, 45.06; H, 3.78; N, 15.99. Found:
C, 45.11; H, 3.10, N, 15.88. IR (KBr): ν = 3422, 3074, 1617,
1478, 1383, 1217 cm−1.
X-ray crystallography
Data for the ligand Naphtpy were collected on a colourless
plate of dimensions 0.28 × 0.08 × 0.02 mm3 at 100 K using a
Bruker APEX II QUAZAR diﬀractometer equipped with a
microfocus multilayer monochromator with Mo Kα radiation
(λ = 0.71073 Å). Data for compounds 1 and 2 were obtained
respectively at 100 and 150 K, on a blue plate of dimensions
0.45 × 0.08 × 0.04 mm3 (1), and on a green needle of
dimensions 0.40 × 0.04 × 0.02 mm3 on a Bruker D8 diﬀract-
ometer using the Advanced Light Source beam-line 11.3.1 at
Lawrence Berkeley National Laboratory, from a silicon
111 monochromator (λ = 0.7749 Å). Data reduction and
absorption corrections were performed with SAINT and
SADABS, respectively.70 The structures were solved and
refined on F2 with the SHELXTL suite.70,71 Non-hydrogen
atoms were refined with anisotropic thermal parameters
while hydrogen atoms were included at calculated positions
and refined with isotropic thermal parameters, except those
on the water molecules on the structures of 1 and 2, which
were found in diﬀerence Fourier maps and refined freely
with their isotropic thermal parameter 1.5 times that of
their carrier oxygen.
Gel electrophoresis
Stock solutions of the copper(II) compounds were prepared in
40 mM HEPES–10 mM MgCl2 buﬀer (pH = 7.2). pBR322
plasmid DNA aliquots (0.2 mg mL−1) in 40 mM HEPES–10 mM
MgCl2 buﬀer were incubated with the complexes for 1 h at
37 °C. Subsequently, ascorbic acid (100 µM in 40 mM HEPES–
10 mM MgCl2 buﬀer) was added (in the case of experiments
without ascorbic acid, this step was skipped) and the resulting
mixture (15 µM DNA b.p. in a 100 mM solution of the
complex) was incubated at 37 °C for an additional hour. Next,
the reaction samples were treated with 4 µL of a quenching
solution (30% (v/v) glycerol; 0.25% (w/v) bromophenol blue
and 0.25% (w/v) xylene cyanol), and then electrophoretized on
agarose gel (1% in TAE buﬀer, Tris-acetate–EDTA) for 2 h at 1.5
V cm−1, using a BIORAD horizontal tank connected to a PHAR-
MACIA GPS 200/400 variable potential power supply. Samples
of free DNA and DNA in the presence of ascorbic acid were
used as controls. Afterwards, the DNA was stained with SYBR®
safe and the gel was photographed with a BIORAD Gel Doc™
EZ Imager.
AFM experiments
pBR322 plasmid DNA was heated just before use at 60 °C for
10 min to obtain a homogeneous distribution of topoisomers.
The stock solutions of the complexes and plasmid DNA, as
well as the reaction samples (namely the DNA-complex–
ascorbic acid mixtures), were prepared as above (see the Gel
electrophoresis section). The AFM samples were prepared by
casting a 5 µL drop of test solution onto freshly cleaved musco-
vite green mica disks as the support. The drop was allowed to
stand undisturbed for 3 min to favour the adsorbate–substrate
interaction. Each DNA-laden disk was rinsed with Milli-Q
water and was blown dry with clean compressed argon gas
directed normal to the disk surface. The samples were stored
over silica prior to AFM imaging.
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ROS-generation studies
Consumption of ascorbic acid (AA). First, a 100 mM phos-
phate buﬀer solution (pH 7.4) was prepared, which was treated
with a Chelex® 100 resin (Bio-Rad) to remove any traces of
metal ions. Next, a copper solution (1 μM CuCl2 or compounds
1–3) was added. The reaction was initiated through the
addition of a solution of AA to a final concentration of 100 μM.
The consumption of AA was followed by its UV absorbance at
265 nm.
Formation of 7-hydroxy-coumarin-3-carboxylic acid
(7-OH-CCA). A solution of the copper catalyst (10 μM CuCl2 or
compounds 1–3) was added to a 1 mM solution of coumarin-3-
carboxylic acid (CCA) in 100 mM phosphate buﬀer solution
(pH 7.4; previously treated with Chelex® 100 resin). The reac-
tion was initiated by the addition of a solution of AA to a final
concentration of 300 μM. The generation of 7-OH-CCA was fol-
lowed by fluorescence spectroscopy through its emission at
500 nm, when excited at 385 nm.
Cell cultures
Human melanoma (A375) and lung (A549), breast (MCF-7),
prostate (PC3), ovary (SKOV3) and colorectal (SW620) adeno-
carcinoma cell lines were purchased from the American Type
Culture Collection (ATCC, Manassas, VA, USA). The cell lines
A549, A375, SKOV3 and SW620 were cultured in DMEM
medium and PC3 in F12 medium. All media were sup-
plemented with 10% heat-inactivated fetal bovine serum (FBS;
Life Technologies, Carlsbad, CA, USA), 100 U mL−1 penicillin,
100 μg mL−1 streptomycin, and 2 mM L-glutamine. The MCF-7
cell line was cultured in DMEM–F12 (HAM) media (1 : 1) sup-
plemented with 5% horse serum (Life Technologies), 100 μM
sodium pyruvate (Sigma-Aldrich Chemical Co., St. Louis, MO,
USA), 10 μg mL−1 insulin (Sigma-Aldrich), 100 U mL−1 penicil-
lin, 100 μg mL−1 streptomycin, and 2 mM L-glutamine. The
media and supplements whenever not stated were bought
from Biological Industries, Beit Haemek, Israel. Cells were
grown at 37 °C under a 5% CO2 atmosphere.
Cell-viability assays
Cells (1 × 105 cells per mL) were seeded in 96-well plates and
allowed to grow for 24 h. For single-point experiments, the
cells were treated with two diﬀerent concentrations, i.e. 10 μM
and 50 μM, of the compounds investigated for 24 and 48 h.
For the dose–response curves, the cells were treated with
diﬀerent concentrations of the compounds; in the range
0.63–80 μM for 24 h. After treatment, a 10 μM solution of MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide;
Sigma-Aldrich) was added to each well and the plates were
incubated at 37 °C for another 4 h. Subsequently, the medium
was removed and the purple formazan crystals were dissolved
in DMSO. Absorbance was measured at 570 nm using a multi-
well plate reader (Multiskan FC, Thermo Scientific). The cell
viability was calculated as follows: viability (%) = [(absorbance
of the treated wells)/(absorbance of the control wells)] × 100.
The IC50 values (which correspond to the compound concen-
trations in µM that produce 50% cell-viability reduction) were
obtained from the dose–response curves using GraphPad
Prism V5.0 for windows (Graphpad Software, San Diego, CA,
USA). All data are shown as the mean value ± S.D. of three
independent experiments for single-point assays and for the
dose–response curves.
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